Cell Biosciences Boosts F Round, Buys Brightwell

5/13/11

Santa Clara, CA-based Cell Biosciences, the life sciences instrument maker that raised $20 million in Series F funding last fall, said yesterday that it has added a $13 million second tranche to the round and used some of the money to acquire Brightwell Technologies, an Ottawa, Ontari0-based maker of protein analysis tools. Essex Woodlands Health Ventures led the second tranche, which was joined by existing investors Novo A/S, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group, and Lansing Brown Investments.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can subscribe to his Google Group or e-mail him at wroush@xconomy.com. Follow @